![](https://monteverdelaw.com/wp-content/uploads/case-logo/pardes-biosciences-inc.png)
Pardes Biosciences, Inc. (Nasdaq: PRDS), relating to its proposed sale to MediPacific, Inc. Under the terms of the agreement, PRDS shareholders are expected to receive at least $2.02 plus an additional cash amount of at most $0.17 in cash per share they own, as well as one non-tradeable CVR.